Last reviewed · How we verify
Calcipotriol plus betamethasone dipropionate ointment
Calcipotriol plus betamethasone dipropionate ointment is a Small molecule drug developed by LEO Pharma. It is currently FDA-approved.
At a glance
| Generic name | Calcipotriol plus betamethasone dipropionate ointment |
|---|---|
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products (PHASE2)
- LEO 90105 Ointment in Japanese Subjects With Psoriasis (PHASE3)
- Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris (PHASE2)
- The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris (PHASE1, PHASE2)
- Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (PHASE3)
- Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel Compared With Tacalcitol Ointment and the Gel Vehicle Alone in Patients With Psoriasis Vulgaris (PHASE3)
- LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis (PHASE3)
- LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcipotriol plus betamethasone dipropionate ointment CI brief — competitive landscape report
- Calcipotriol plus betamethasone dipropionate ointment updates RSS · CI watch RSS
- LEO Pharma portfolio CI
Frequently asked questions about Calcipotriol plus betamethasone dipropionate ointment
What is Calcipotriol plus betamethasone dipropionate ointment?
Calcipotriol plus betamethasone dipropionate ointment is a Small molecule drug developed by LEO Pharma.
Who makes Calcipotriol plus betamethasone dipropionate ointment?
Calcipotriol plus betamethasone dipropionate ointment is developed and marketed by LEO Pharma (see full LEO Pharma pipeline at /company/leo-pharma).
What development phase is Calcipotriol plus betamethasone dipropionate ointment in?
Calcipotriol plus betamethasone dipropionate ointment is FDA-approved (marketed).